Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

inue to work closely with our HCV partner, Roche, and the FDA on the development and regulatory review of R7128, which has demonstrated compelling antiviral activity and has been generally well-tolerated in clinical trials to date."

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys(R) and Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 Phase 1 Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... needle commonly used with a syringe to inject substances ... it. A hypodermic needle is used for rapid delivery ... ingested. Hypodermic needles are broadly classified into non-safety and ...
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... September 30, 2011. "We are focused on ... complete response letter around year-end and filing the lorcaserin ... the first half of next year," stated Jack Lief, ...
... China Kanghui Holdings (NYSE: KH ) ("Kanghui" or ... orthopedic implants in China, today announced financial results for the ... Highlights Total net revenue for the third ... from RMB63.6 million in the corresponding period of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 7Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 8China Kanghui Holdings Reports Third Quarter 2011 Financial Results 2China Kanghui Holdings Reports Third Quarter 2011 Financial Results 3China Kanghui Holdings Reports Third Quarter 2011 Financial Results 4China Kanghui Holdings Reports Third Quarter 2011 Financial Results 5China Kanghui Holdings Reports Third Quarter 2011 Financial Results 6China Kanghui Holdings Reports Third Quarter 2011 Financial Results 7China Kanghui Holdings Reports Third Quarter 2011 Financial Results 8China Kanghui Holdings Reports Third Quarter 2011 Financial Results 9China Kanghui Holdings Reports Third Quarter 2011 Financial Results 10China Kanghui Holdings Reports Third Quarter 2011 Financial Results 11China Kanghui Holdings Reports Third Quarter 2011 Financial Results 12China Kanghui Holdings Reports Third Quarter 2011 Financial Results 13China Kanghui Holdings Reports Third Quarter 2011 Financial Results 14
(Date:7/13/2014)... treatment and variations in the quality of care are ... patients still varies widely between regions within Europe, according ... adults to date, published in The Lancet Oncology ... for most cancers of the blood has increased over ... of new targeted drugs in the early 2000s such ...
(Date:7/13/2014)... type-1 diabetes could improve patient care worldwide and ... the device,s inventors at the Stanford University School ... be published online July 13 in Nature ... type-1 diabetes outside hospital settings. The handheld microchips ... mellitus, which are both characterized by high blood-sugar ...
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on the ... rendering; Layout and Animation; Image Reconstruction]: Global Advancements, ... analyzes and studies the major market drivers, restraints, ... Europe, Middle East and Africa, Asia-Pacific and Latin ... of the 3D imaging market, providing an in-depth ...
(Date:7/13/2014)... The federal court overseeing thousands of ... against Johnson & Johnson’s Ethicon, Inc. is preparing to ... to get underway next month. According to an Amended ... Southern District of West Virginia on July 9, 2014, ... 2014 at 3:00 p.m. July selection is slated to ...
Breaking Medicine News(10 mins):Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4
... an approved clot-busting drug remains the most beneficial proven ... ,The Guidelines for the Early Management ... options – such as intra-arterial administration of clot-busting drugs ... ,The guidelines focus on the crucial ...
... may hold the key to not only stopping heart ... ever occurring//. Researchers at Mount Sinai School of Medicine ... with a novel contrast agent know as N1177 can ... stroke. The findings may help physicians diagnosis a heart ...
... resistance after the failure of an anti-HIV drug combination is ... cell losses, according to a study of patients failing treatment ... the study also found that on average, patients who remained ... choice still available to them for every six months on ...
... special envoy for the fight against tuberculosis, on Tuesday called ... the spread of TB and HIV in Africa.// ... that the two diseases are spreading rapidly across the continent ... assistance. "We are providing antiretrovirals to as many people as ...
... has evolved to become resistant to all classes of antibiotics ... U.S. Centers for Disease Control and Prevention (CDC) has said ... due to the emergence of drug-resistant strains in ... remains as there is no indication so far that the ...
... - artificial legs made in Rajasthan - is all set to ... ,Experts from the Bhagwan Mahaveer Viklang Sahayta Samiti (BMVSS) ... Indian contingent of the UN peacekeeping force in Lebanon, BMVSS general ... a camp in Lebanon April 14 to 25. Five technicians would ...
Cached Medicine News:Health News:Intravenous Delivery of Clot-busting Drug Still Best Intervention for Ischemic Stroke 2Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 2Health News:Is There Any Clinical Benefit to Staying on a Failing Regimen? 3Health News:Jaipur Foot Takes Off for Lebanon 2
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
Straight, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tu...
20 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Medicine Products: